Close
Almac
Achema middle east

Articles

Influenza Is Nothing to Sneeze At

The Zika virus is considered a major global health risk, as infection during pregnancy is associated with babies born with microcephaly. The 2014 Ebola outbreak in West Africa killed over 11,300 people, despite not being spread...

Auditory Therapy, Ototoxicity and GLP Compliance Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve?

The numbers are daunting – 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly. Hearing loss presents a growing public health problem, due to ageing and an urban way...

Direct-to-Patient Solutions Assuring Patient Participation and Retention in Clinical Trials

The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just...

Asia’s increasing levels of clinical trial industry competition are to your benefit

Biotechnology and pharmaceutical companies within the United States and Europe face an increasing number of hurdles when undertaking clinical trials within their own country or region; problems such as over saturated patient pools, difficulties meeting and maintaining enrollment numbers, increasing costs and lengthy time delays. While clinical trials...

Time for a Different Approach to Quality Systems in Biopharmaceutical Manufacturing

Despite the wide array of information systems available for biopharmaceutical manufacturing, we need to adopt a “follow-the-workflow” approach to overcome the process inefficiencies generated by quality and production silos. For the better part of thirty years, a critical component of...

New centre is tackling manufacturing challenge of cell therapy field

Stem cell science has made huge progress since the early 1960s when Canadian researchers James Till and Ernest McCulloch discovered blood stem cells and advanced medical research across the globe. Today, the Alliance for Regenerative Medicine estimates there are more...

Nativis’ platform aims to transform disease treatment on a global scale – “a symphony of cures”

In late 2015, I was approached by the board of Nativis, Inc.to take on the leadership of the company, by then a 13-year-old “startup.” I had already been on the board of directors for over two years and through first-hand...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »